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cocci except E. faecalis, although a few strains of 
staphylococci and E. faecium with acquired resistance 
contingent on efflux or acetylation of dalfopristin. 
Linezolid has near-universal activity against gram- 
positive cocci, with MICs narrowly distributed from 0.5 
-4 mg/L. Linezolid-resistance has only been encountered 
in a few mutants of enterococci and one MRSA, 
virtually all of them selected during therapy in under- 
dosed patients or those with indwelling devices or 
difficult-to-reach infections. 
Agents such as linezolid give vital new options 
against gram-positive bacteria. Increasingly, therefore, 
the centre of concern must swing back to gram-negative 
bacteria, where pan-resistance is emerging in a few non- 
fermenters - mostly P aeruginosa from cystic fibrosis in 
the West, but more widely among pseudomonads and 
Acinetobacter spp. in East Asia. Against these organisms 
there is a dearth of advanced antimicrobial develop- 
ments although carbapenemase inhibitors, efflux in- 
hibitors and antimicrobial peptides all provide prospects 
for the more distant future. 
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Infections with a variety of agents cause major prob- 
lems in the immunocompromised host. In addition to 
infection control techniques, a number of strategies 
utilizing antimicrobial agents have been employed: 
therapeutic use for documented infections; preemptive 
use for suspected infections; and prophylactic use 
to prevent infection in high-risk patients. Among 
the major risk factors for bacterial infections in the 
immunocompromised host are neutropenia, breakdown 
in mucosal protective barriers secondary to immuno- 
suppressive agents, and contamination of surgical 
procedures (especially in solid organ transplants) as 
well as the further immunosuppressive effects of 
opportunistic (especially viral) infections. It is the use of 
antimicrobial agents in this setting that is the major 
factor in selecting for resistant bacteria. In some cases, 
the organisms emerge because they are not included 
in the spectrum of activity of the drug being utilized. 
In other cases, antibiotic use results in the selection of 
resistant bacteria originally in the spectrum of the 
agent being utilized. Examples of this are seen in the 
studies in which earlier generation fluoroquinolones 
(which lacked outstanding coverage against Gram- 
positive bacteria) were used for prophylaxis in neutro- 
penic patients; and as a result of this, the patients 
undergoing such prophylaxis showed a marked increase 
in incidence of infections due to viridans streptococci. 
The addition of penicillin to the regimen initially 
suppressed the viridans streptococcal infections, but 
resulted in the emergence of penicillin-resistant viridans 
streptococci. Indeed, it is often possible to predict the 
organisms likely to emerge in the setting of extensive 
antimicrobial use for therapy or prophylaxis. Extensive 
use of expanded-spectrum cephalosporins often results 
in the emergence of Enterobacter cloacae, Entero- 
bacteriaceae with extended-spectrum beta-lactamases, 
vancomycin-resistant enterococci, and nonfermenting 
organisms such as B. cepacia, Acinetobacter species, 
etc. The use of beta-lactam/beta-lactamase inhibitors 
often results in the emergence of MRSA, or Entero- 
bacteriaceae with inhibitor-resistant beta-lactamases. 
Substituting carbapenems also selects for MRSA, 
Stenotrophomonas maltophilia, Serratia marcescens with 
carbapenemases, or vancomycin-resistant Enterococcus 
faecium. As noted before, the earlier generation fluoro- 
quinolones often selected Gram-positive organisms, 
but the newer fluoroquinolones can select for MRSA, 
or fluoroquinolone-resistant Enterobacteriaceae and/or 
Pseudomonas aeruginosa. Extensive use of vancomycin 
or teicoplanin is responsible for the emergence of 
vancomycin-resistant enterococci and strains of S. 
aureus with intermediate resistance to glycopeptides 
(GISA). Many of these organisms are Gram-negative, 
but the Gram-positive bacteria have become a major 
problem in the immunocompromised host in recent 
years. Among the important Gram-positive organisms 
causing problems in this setting are methicillin- and 
fluoroquinolone-resistant S. aureus, methicillin-resistant 
coagulase-negative staphylococci, beta-lactam-resistant 
viridans streptococci, and vancomycin-resistant entero- 
cocci. Interestingly, three of the four of these organisms 
are bacteria that are usually considered to be of relatively 
low virulence and are part of the normal human bacterial 
flora. However, it is the resistance to antimicrobial 
agents in these organisms that makes them dangerous in 
the immunocompromised host. 
The development of resistance to antimicrobial agents 
in bacteria occurs by one of two mechanisms: chromo- 
somal mutation or dissemination of resistance genes 
among microorganisms. These two mechanisms of 
resistance have clinical significance. Emergence caused 
by chromosomal mutation is a rare event and is stable 
when it occurs. It involves a single strain, a single 
resistance gene and is selected for at the site of infection. 
It is selected by a specific antimicrobial given to a specific 
patient and the resistant clones can lead to therapeutic 
failure or disseminate through cross-infection. Antibiotic 
combinations may prevent the selection of resistance 
due to chromosomal mutation. On the other hand, 
resistance related to the dissemination of resistance 
genes among microorganisms (eg, plasmid- or trans- 
poson-mediated resistance) is a relatively frequent event 
and of variable stability. It involves two strains of bacteria 
and often involves multiple resistance determinants. 
Selection is frequently at a site other than that of 
2S4 International Journal of Infectious Diseases I Volume 6, Supplement 2,2002 
infection (ie, in the gut or the environment) and it may 
be selected for by as many antimicrobials as there are 
resistance determinants in a given plasmid or transposon. 
The resistant strains may lead to superinfection; and 
dissemination of the resistance may occur by spread 
of the resistant strain, or by spread of the resistance 
determinants to other bacteria. Antibiotic combinations 
are unlikely to prevent this type of resistance and may 
even enhance the selection of resistant strains. Ihe 
likelihood of developing resistance during therapy 
depends upon the resistance mechanism and the genetic 
constitution of the infecting organism. Thus, acquisition 
of new resistance genes during therapy is quite unlikely. 
Mutation involving ribosomal binding sites of bacteria 
are selected with relatively high frequency in organisms 
with low copy number of ribosomal genes such as 
Helicobacterpylori and Mycobacterium tuberculosis and 
other mycobacteria. However, mutational resistance due 
to ribosomal binding site changes is much less likely in 
organisms such as staphylococci and enterococci which 
have a high copy number of ribosomal genes. 
The Enterococcus is a beautiful paradigm of an 
organism highly equipped to survive in the antibiotic 
era. Enterococci are intrinsically resistant to beta- 
lactams and have low-level intrinsic resistance to amino- 
glycosides and lincosamides. They have acquired 
resistance to virtually every other antibiotic (including 
newer agents such as quinupristimdalfopristin and 
even linezolid). Among the types of bacterial resistance 
acquired by the enterococci, none is more remarkable 
than its acquisition of resistance to vancomycin. In order 
to do this, the Enterococcus basically had to acquire 
genes that enabled it to synthesize unique cell wall 
precursors which would not bind vancomycin. Genes 
found in vancomycin-resistant enterococci are not native 
enterococcal genes, but likely have been acquired from 
a variety of cryptic anaerobes that are part of normal 
lIora and are difficult, if not impossible to identify by 
current cultural techniques. Resistance to penicillin 
in viridans streptococci is the result of mutations in 
penicillin-binding proteins that decrease affinity for 
penicillin. The fact that viridans streptococci could 
develop penicillin resistance in the presence of pressure 
from continuous heavy use of penicillin and other beta- 
lactams has been known since the 1970s when penicillin- 
resistant strains were noted to cause endocarditis in 
patients receiving continuous penicillin prophylaxis to 
prevent recurrence of rheumatic fever. The significance 
of resistance in viridans streptococci is enhanced by 
the fact that genes or portions of genes from viridans 
streptococci have clearly been transferred into pneumo- 
cocci and the resultant mosaic genes in pneumococci are 
the cause of penicillin resistance in this organism. 
Resistance to methicillin in staphylococci is related to 
the acquisition of a gene which encodes a penicillin- 
binding protein (PBP2) that has markedly decreased 
affinity for methicillin. The genetic control of this gene 
is complicated. More recently, strains of S. aureus with 
intermediate levels of resistance to glycopeptides have 
been described:, Although the exact mechanism of 
resistance in these strains is not known, it undoubtedly 
involves a series of mutations that ultimately decrease 
the effectiveness of penicillin-binding protein 4 and thus 
decrease cross linking of the cell wall. This results in 
uncrossed linked polymers which bind vancomycin or 
teicoplanin like a sponge. More recent studies have 
shown that virtually all of the GISA strains identified to 
date are of a similar agr type group (Group 2) and that 
these strains have mutations in agr function that alters 
their virulence and gives them enhanced ability to pro- 
duce biofilm and adhere to foreign substances. 
It is clear from the above that bacteria have a remark- 
able ability to develop resistance to antimicrobial agents. 
This leads to a continuous challenge to utilize antimicro- 
bial agents effectively and to look for antimicrobial 
agents active against new targets in resistant bacteria. 
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Cancer patients are prone to infections caused by 
Gram-positive cocci, in particular coagulase-negative 
staphylococci and viridans streptococci. This is due 
to the frequent long-term use of central venous 
catheters, severe mucosal damage from aggressive 
chemotherapy and the widely applied oral antimicrobial 
prophylaxis aimed at Gram-negative aerobic pathogens. 
As resistance to beta-lactam antibiotics among Gram- 
positive pathogens grew continuously over the past 
decade, clinicians relied increasingly on glycopeptides 
especially in neutropenic patients with malignancies-a 
patient population that is at increased risk for the 
development of resistant strains. Consequently, reports 
of vancomycin and teicoplanin resistance increased in 
both enterococci and staphylococci, making it necessary 
to reconsider the empiric use of glycopeptides and to 
evaluate new antimicrobial treatment strategies in these 
patients. 
Linezolid is the first oxazolidinone, a new synthetic 
class of antimicrobials, and is highly active against Gram- 
positive cocci including resistant strains. In a series of 
multinational, comparative clinical trials linezolid has 
been shown to be efficacious and safe in complicated skin 
and soft tissue infections, nosocomial pneumonia, and 
bacteremia.These data suggested that linezolid may serve 
as a useful addition to the therapeutic armamentarium 
for the treatment of infections in immunocompromised 
patients with malignancies. First results of studies in this 
patient group have shown promise. 
Smith et al* investigated the efficacy of iinezolid 
600 mg IV every 12 hours in 65 neutropenic patients 
